6
Oct
2022

Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

RevMed’s Rollout, Yosemite Invests in Cancer & Servier’s Phase III Whiff
Anthropic Makes Noise, Silence Gets Bought, & GSK Gets HepB OK
BMS Hits IPF Goal, Iambic and City IPO & AZ Invests in Insitro
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO